{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:28:33Z","timestamp":1760146113705,"version":"build-2065373602"},"reference-count":56,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Federal University of Paran\u00e1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>(1) Background: After the COVID-19 pandemic, there is concern regarding the immunity of the population to SARS-CoV-2 variants, particularly the Omicron variant and its sub-lineages. (2) Methods: The study involved analyzing the immune response and symptomatology of 27 vaccinated individuals who were subsequently infected by Omicron sub-lineages. Blood samples were collected for serological analysis, including the detection of IgG antibodies reactive to the Nucleocapsid (N) and Spike (S) antigens of SARS-CoV-2. Additionally, participants were interviewed to assess the intensity of symptoms during the infection. (3) Results: Despite the high levels of anti-Spike IgG observed after vaccination, all participants were infected by Omicron sub-lineages. The most common symptoms reported by participants were fever or chills, sore throat, and cough. The levels of anti-Spike IgG found prior to infection did not correlate with symptom intensity post-infection. However, it was observed that high post-infection anti-Nucleocapsid IgG levels correlated with mild symptoms during the course of the disease, suggesting a potential role for anti-N antibodies in symptom intensity. (4) Conclusions: In line with previous studies, the high levels of IgG anti-Spike resulting from vaccination did not provide complete protection against infection by the Omicron variant. Additionally, our data suggest that anti-Nucleocapsid IgG titers are negatively correlated with the intensity of the symptoms during mild infections.<\/jats:p>","DOI":"10.3390\/vaccines12101149","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T12:02:10Z","timestamp":1728388930000},"page":"1149","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Symptomatology and IgG Levels before and after SARS-CoV-2 Omicron Breakthrough Infections in Vaccinated Individuals"],"prefix":"10.3390","volume":"12","author":[{"given":"Nigella M.","family":"Paula","sequence":"first","affiliation":[{"name":"Setor Litoral, Federal University of Paran\u00e1\u2014UFPR, Matinhos 83260-00, PR, Brazil"},{"name":"Graduated Program in Sciences-Biochemistry, Federal University of Paran\u00e1\u2014UFPR, Curitiba 81530-00, PR, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7339-9476","authenticated-orcid":false,"given":"Emerson","family":"Joucoski","sequence":"additional","affiliation":[{"name":"Setor Litoral, Federal University of Paran\u00e1\u2014UFPR, Matinhos 83260-00, PR, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valter A.","family":"Baura","sequence":"additional","affiliation":[{"name":"Graduated Program in Sciences-Biochemistry, Federal University of Paran\u00e1\u2014UFPR, Curitiba 81530-00, PR, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuel M.","family":"Souza","sequence":"additional","affiliation":[{"name":"Graduated Program in Sciences-Biochemistry, Federal University of Paran\u00e1\u2014UFPR, Curitiba 81530-00, PR, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3711-969X","authenticated-orcid":false,"given":"Fabio O.","family":"Pedrosa","sequence":"additional","affiliation":[{"name":"Graduated Program in Sciences-Biochemistry, Federal University of Paran\u00e1\u2014UFPR, Curitiba 81530-00, PR, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8459-3437","authenticated-orcid":false,"given":"Alan G.","family":"Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"Setor Litoral, Federal University of Paran\u00e1\u2014UFPR, Matinhos 83260-00, PR, Brazil"},{"name":"Graduated Program in Farmacy-Biochemistry, Federal University of Paran\u00e1\u2014UFPR, Curitiba 81530-00, PR, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7587-9510","authenticated-orcid":false,"given":"Luciano F.","family":"Huergo","sequence":"additional","affiliation":[{"name":"Setor Litoral, Federal University of Paran\u00e1\u2014UFPR, Matinhos 83260-00, PR, Brazil"},{"name":"Graduated Program in Sciences-Biochemistry, Federal University of Paran\u00e1\u2014UFPR, Curitiba 81530-00, PR, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s42269-021-00607-w","article-title":"A systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population","volume":"45","author":"Iheanacho","year":"2021","journal-title":"Bull. Natl. Res. Cent."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1473-3099(22)00140-2","article-title":"Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: A test-negative, case-control study","volume":"22","author":"Andrews","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41591-022-01701-w","article-title":"Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil","volume":"28","author":"Katikireddi","year":"2022","journal-title":"Nat. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1473-3099(22)00800-3","article-title":"Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: A randomised, observer-masked, controlled trial in Indonesia","volume":"23","author":"Fadlyana","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_6","first-page":"100474","article-title":"The effectiveness of COVID-19 vaccines in Latin America, 2021: A multicenter regional case-control study","volume":"20","author":"Kahn","year":"2023","journal-title":"Lancet Reg. Health Am."},{"key":"ref_7","first-page":"100465","article-title":"The effectiveness of COVID-19 vaccines against severe cases and deaths in Brazil from 2021 to 2022: A registry-based study","volume":"20","author":"Valiati","year":"2023","journal-title":"Lancet Reg. Health Am."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"eabf2467","DOI":"10.1126\/sciadv.abf2467","article-title":"Longitudinal antibody repertoire in \u201cmild\u201d versus \u201csevere\u201d COVID-19 patients reveals immune markers associated with disease severity and resolution","volume":"7","author":"Ravichandran","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Wu, J., Liang, B.-Y., Fang, Y.-H., Wang, H., Yang, X.-L., Shen, S., Chen, L.-K., Li, S.-M., Lu, S.-H., and Xiang, T.-D. (2021). Occurrence of COVID-19 Symptoms During SARS-CoV-2 Infection Defines Waning of Humoral Immunity. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.722027"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00430-023-00763-y","article-title":"The quantity and quality of anti-SARS-CoV-2 antibodies show contrariwise association with COVID-19 severity: Lessons learned from IgG avidity","volume":"212","author":"Hajilooi","year":"2023","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Paula, N.M., Conzentino, M.S., Gon\u00e7alves, A.C.A., da Silva, R., Weissheimer, K.V., Kluge, C.H.S., Marins, P.H.S.A., Camargo, H.S.C., Farias, L.R.P., and Sant\u2019ana, T.P. (2023). Population-Based Analysis of the Immunoglobulin G Response to Different COVID-19 Vaccines in Brazil. Vaccines, 11.","DOI":"10.3390\/vaccines11010021"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJMoa2200674","article-title":"Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine","volume":"386","author":"Moreira","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1016\/S2666-5247(21)00305-0","article-title":"Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: A prospective, longitudinal population-based study","volume":"3","author":"Barin","year":"2022","journal-title":"Lancet Microbe"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Pratesi, F., Caruso, T., Testa, D., Tarpanelli, T., Gentili, A., Gio\u00e8, D., and Migliorini, P. (2021). BNT162b2 mRNA SARS-CoV-2 Vaccine Elicits High Avidity and Neutralizing Antibodies in Healthcare Workers. Vaccines, 9.","DOI":"10.3390\/vaccines9060672"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: Results of a systematic review and meta-regression","volume":"399","author":"Feikin","year":"2022","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Ssentongo, P., Ssentongo, A.E., Voleti, N., Groff, D., Sun, A., Ba, D.M., Nunez, J., Parent, L.J., Chinchilli, V.M., and Paules, C.I. (2022). SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: A systematic review and meta-analysis. BMC Infect. Dis., 22.","DOI":"10.1186\/s12879-022-07418-y"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(21)01642-1","article-title":"Spike-antibody waning after second dose of BNT162b2 or ChAdOx1","volume":"398","author":"Shrotri","year":"2021","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months","volume":"385","author":"Levin","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/CM9.0000000000001892","article-title":"Reinfection rates among patients previously infected by SARS-CoV-2: Systematic review and meta-analysis","volume":"135","author":"Mao","year":"2022","journal-title":"Chin. Med. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(21)00575-4","article-title":"Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: A population-level observational study","volume":"397","author":"Hansen","year":"2021","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1473-3099(22)00143-8","article-title":"Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: A retrospective, total population cohort study in Sweden","volume":"22","author":"Ballin","year":"2022","journal-title":"Lancet Infect Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"taac109","DOI":"10.1093\/jtm\/taac109","article-title":"Duration of immune protection of SARS-CoV-2 natural infection against reinfection","volume":"29","author":"Chemaitelly","year":"2022","journal-title":"J. Travel. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41586-021-04005-0","article-title":"High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape","volume":"600","author":"Schmidt","year":"2021","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/s41591-022-01715-4","article-title":"Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern","volume":"28","author":"Wratil","year":"2022","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa2203965","article-title":"Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections","volume":"387","author":"Altarawneh","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Freire-Neto, F.P., Teixeira, D.G., da Cunha, D.C.S., Morais, I.C., Tavares, C.P.M., Gurgel, G.P., Medeiros, S.D.N., dos Santos, D.C., Sales, A.D.O., and Jeronimo, S.M.B. (2022). SARS-CoV-2 reinfections with BA.1 (Omicron) variant among fully vaccinated individuals in northeastern Brazil. PLoS Negl. Trop. Dis., 16.","DOI":"10.1371\/journal.pntd.0010337"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Oliveira, J.R., Ruiz, C.M.R., Machado, R.R.G., Magawa, J.Y., Daher, I.P., Urbanski, A.H., Schmitz, G.J.H., Arcuri, H.A., Ferreira, M.A., and Sasahara, G.L. (2023). Immunodominant antibody responses directed to SARS-CoV-2 hotspot mutation sites and risk of immune escape. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1010105"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Rhoden, J., Hoffmann, A.T., Stein, J.F., da Silva, M.S., Gularte, J.S., Filippi, M., Demoliner, M., Girardi, V., Spilki, F.R., and Fleck, J.D. (2024). Diversity of Omicron sublineages and clinical characteristics in hospitalized patients in the southernmost state of Brazil. BMC Infect. Dis., 24.","DOI":"10.1186\/s12879-024-09089-3"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/imr.13089","article-title":"Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines","volume":"310","author":"Sette","year":"2022","journal-title":"Immunol. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"eabi6950","DOI":"10.1126\/sciimmunol.abi6950","article-title":"Distinct antibody and memory B cell responses in SARS-CoV-2 na\u00efve and recovered individuals following mRNA vaccination","volume":"6","author":"Goel","year":"2021","journal-title":"Sci. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"R918","DOI":"10.1016\/j.cub.2021.06.049","article-title":"The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic","volume":"31","author":"Otto","year":"2021","journal-title":"Curr. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.ijid.2021.03.005","article-title":"Infection sustained by lineage B.1.1.7 of SARS-CoV-2 is characterised by longer persistence and higher viral RNA loads in nasopharyngeal swabs","volume":"105","author":"Calistri","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Zhang, D., Zhong, J., Xiong, H., Li, Y., Guo, T., Peng, B., Fang, C., Kang, Y., Tan, J., and Ma, Y. (2023). Protective Effect of Inactivated COVID-19 Vaccines against Omicron BA.2 Infection in Guangzhou: A Test-Negative Case-Control Real-World Study. Vaccines, 11.","DOI":"10.3390\/vaccines11030566"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Garrett, N., Tapley, A., Andriesen, J., Seocharan, I., Fisher, L.H., Bunts, L., Espy, N., Wallis, C.L., Randhawa, A.K., and Ketter, N. (2022). High Rate of Asymptomatic Carriage Associated with Variant Strain Omicron. medRxiv.","DOI":"10.1101\/2021.12.20.21268130"},{"key":"ref_36","first-page":"162","article-title":"SARS-CoV-2 variant biology: Immune escape, transmission and fitness","volume":"21","author":"Carabelli","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41579-023-00878-2","article-title":"The evolution of SARS-CoV-2","volume":"21","author":"Markov","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.cell.2022.06.005","article-title":"Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum","volume":"185","author":"Tuekprakhon","year":"2022","journal-title":"Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e01026-22","DOI":"10.1128\/spectrum.01026-22","article-title":"SARS-CoV-2 Seroconversion in Response to Infection and Vaccination: A Time Series Local Study in Brazil","volume":"10","author":"Huergo","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s42770-022-00753-x","article-title":"A magnetic bead immunoassay to detect high affinity human IgG reactive to SARS-CoV-2 Spike S1 RBD produced in Escherichia coli","volume":"53","author":"Conzentino","year":"2022","journal-title":"Braz. J. Microbiol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Conzentino, M.S., Santos, T.P., Selim, K.A., Wagner, B., Alford, J.T., Deobald, N., Paula, N.M., Rego, F.G., Zanette, D.L., and Aoki, M.N. (2021). Ultra-fast, high throughput and inexpensive detection of SARS-CoV-2 seroconversion using Ni2+ magnetic beads. Anal. Biochem., 631.","DOI":"10.1016\/j.ab.2021.114360"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1021\/acssensors.0c02544","article-title":"Magnetic Bead-Based Immunoassay Allows Rapid, Inexpensive, and Quantitative Detection of Human SARS-CoV-2 Antibodies","volume":"3","author":"Huergo","year":"2021","journal-title":"ACS Sens."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1007\/s42770-021-00556-6","article-title":"Antigen production and development of an indirect ELISA based on the nucleocapsid protein to detect human SARS-CoV-2 seroconversion","volume":"52","author":"Conzentino","year":"2021","journal-title":"Braz. J. Microbiol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Bochnia-Bueno, L., De Almeida, S.M., Raboni, S.M., Adamoski, D., Amadeu, L.L.M., Carstensen, S., and Nogueira, M.B. (2022). Dynamic of humoral response to SARS-CoV-2 anti-Nucleocapsid and Spike proteins after CoronaVac vaccination. Diagn. Microbiol. Infect. Dis., 102.","DOI":"10.1101\/2021.05.20.21255825"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/s41564-020-0770-5","article-title":"A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology","volume":"5","author":"Rambaut","year":"2020","journal-title":"Nat. Microbiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/s41591-022-01721-6","article-title":"Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines","volume":"28","author":"Wei","year":"2022","journal-title":"Nat. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e233370","DOI":"10.1001\/jamanetworkopen.2023.3370","article-title":"Analysis of Previous Infection, Vaccinations, and Anti-SARS-CoV-2 Antibody Titers and Protection Against Infection With the SARS-CoV-2 Omicron BA.5 Variant","volume":"6","author":"Yamamoto","year":"2023","journal-title":"JAMA Netw. Open."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/s41577-022-00809-x","article-title":"The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses","volume":"23","author":"Murray","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1016\/S2666-5247(22)00390-1","article-title":"Efficacy of SARS-CoV-2 vaccines and the dose-response relationship with three major antibodies: A systematic review and meta-analysis of randomised controlled trials","volume":"4","author":"Yang","year":"2023","journal-title":"Lancet Microbe"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Buhre, J.S., Pongracz, T., K\u00fcnsting, I., Lixenfeld, A.S., Wang, W., Nouta, J., Lehrian, S., Schmelter, F., Lunding, H.B., and D\u00fchring, L. (2023). mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1020844"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/s41564-023-01505-9","article-title":"Immune imprinting and next-generation coronavirus vaccines","volume":"8","author":"Huang","year":"2023","journal-title":"Nat. Microbiol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Kang, H., Jung, J., Ko, G.Y., Lee, J., and Oh, E.-J. (2024). Evaluation of Long-Term Adaptive Immune Responses Specific to SARS-CoV-2: Effect of Various Vaccination and Omicron Exposure. Vaccines, 12.","DOI":"10.3390\/vaccines12030301"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Goguet, E., Olsen, C.H., Meyer, W.A., Ansari, S., Powers, J.H., Conner, T.L., Coggins, S.A., Wang, W., Wang, R., and Illinik, L. (2024). Immune and behavioral correlates of protection against symptomatic post-vaccination SARS-CoV-2 infection. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1287504"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s15010-024-02189-x","article-title":"Protective role of SARS-CoV-2 anti-S IgG against breakthrough infections among European healthcare workers during pre and post-Omicron surge-ORCHESTRA project","volume":"52","author":"Spiteri","year":"2024","journal-title":"Infection"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e156713","DOI":"10.1172\/jci.insight.156713","article-title":"Anti-nucleocapsid antibody levels and pulmonary comorbid conditions are linked to post-COVID-19 syndrome","volume":"7","author":"Jia","year":"2022","journal-title":"JCI Insight"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/10\/1149\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:09:03Z","timestamp":1760112543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/10\/1149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":56,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["vaccines12101149"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12101149","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2024,10,8]]}}}